QTRX

Quanterix is a Simoa/spatial-biology life-science tools company whose fundamentals deteriorated sharply in FY2025. Revenue was essentially flat ($138.9M, +1.1% YoY) while the net loss nearly tripled to -$107.2M (from -$38.5M), operating margin collapsed to -90.4%, and gross margin fell 21.8% to 46.8% — a bad combination of no top-line growth and worsening unit economics. The FY2021-2025 history shows revenue creeping from $111M to $139M over four years with losses that never went away and just widened again, so this is not a company that has demonstrated a path to profitable scale.

The balance sheet is the sharper worry. Cash fell 47.4% to just $29.8M while operating cash flow was -$77.2M — a burn rate that dwarfs the cash line. Current assets of $212M (vs. $74.8M current liabilities) and $296M equity mean this isn't an imminent solvency event, but management itself flags in the MD&A that it 'expect[s] to incur operating losses into 2026' and that the hoped-for 'cash flow breakeven in 2026' is explicitly 'dependent on our success in meeting both revenue and expense objectives.' That is a conditional, not a plan you can underwrite. Shares already grew 21.1% in the year, and the accumulated deficit deepened to -$577M, so continued dilution to fund the burn is a live risk.